Bioavailability and in vivo efficacy of a praziquantel–polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European journal of drug metabolism and pharmacokinetics

• Publication date

  2012-03-30

• Fields of study

  Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1007/s13318-012-0089-6PMID 22460595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE MECHANISM OF DRUG RELEASE FROM SOLID DISPERSION IN WATER-SOLUBLE POLYMER

  2012cited by this paper
• Comparative efficacy and bioavailability of different praziquantel brands.

  2011cited by this paper
• Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs

  2009cited by this paper
• Taste, A New Incentive to Switch to (R)-Praziquantel in Schistosomiasis Treatment

  2009cited by this paper
• Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis

  2008cited by this paper
• Chemotherapy of schistosomiasis: present and future.

  2007influential reference
• DRUG-METABOLIZING ENZYMES AND PRAZIQUANTEL BIOAVAILABILITY IN MICE HARBORING SCHISTOSOMA MANSONI ISOLATES OF DIFFERENT DRUG SUSCEPTIBILITIES

  2006cited by this paper
• Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method.

  2005cited by this paper
• Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination.

  2004cited by this paper
• Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates.

  2004influential reference
• Effect of artemether alone and in combination with grapefruit juice on hepatic drug-metabolising enzymes and biochemical aspects in experimental Schistosoma mansoni.

  2004cited by this paper
• Sustained-release praziquantel tablet: pharmacokinetics and the treatment of clonorchiasis in beagle dogs

  2003cited by this paper
• Drugs for the control of parasitic diseases: current status and development in schistosomiasis.

  2003cited by this paper
• Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

  2003cited by this paper
• The mechanisms of drug release from solid dispersions in water-soluble polymers.

  2002cited by this paper
• Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections

  2001cited by this paper
• Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel.

  2001cited by this paper
• In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel.

  2001cited by this paper
• Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions.

  2001cited by this paper
• Effect of Schistosoma mansoni Infection and Treatment on Drug Metabolizing Enzymes

  2000influential reference
• Preparation, Dissolution and Characterization of Praziquantel Solid Dispersions

  1999cited by this paper
• Dissolution properties of praziquantel--PVP systems.

  1998cited by this paper
• Different levels of Schistosoma mansoni infection induce changes in drug-metabolizing enzymes

  1998cited by this paper
• Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30

  1998cited by this paper
• Spectroscopic Characterization of Interactions Between PVP and Indomethacin in Amorphous Molecular Dispersions

  1997cited by this paper
• Dissolution rate of furosemide from polyethylene glycol solid dispersions.

  1997cited by this paper
• Albendazole versus ricobendazole (albendazole-sulphoxide) against enteral and parenteral stages of Trichinella spiralis in mice.

  1997cited by this paper
• Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.

  1996cited by this paper
• Preparation, dissolution and characterization of albendazole solid dispersions

  1996cited by this paper
• Clinical and Pharmacokinetic Study of Praziquantel in Egyptian Schistosomiasis Patients With and Without Liver Cell Failure

  1995cited by this paper
• Characterization and dissolution of fenofibrate solid dispersion systems

  1994cited by this paper
• Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure.

  1994cited by this paper
• Possible Mechanisms of Alteration in the Capacities of Carcinogen Metabolizing Enzymes during Schistosomiasis and Their Role in Bladder Cancer Induction

  1993cited by this paper
• Liposomal delivery system for the targeting and controlled release of praziquantel

  1992cited by this paper
• Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis.

  1990influential reference
• Altered drug metabolism in parasitic diseases.

  1988influential reference
• Application of differential scanning calorimetry to the study of solid drug dispersions.

  1985influential reference
• Amorphous spray‐dried hydroflumethiazide‐polyvinylpyrrolidone systems: Physicochemical properties

  1984cited by this paper
• Quantitative determination of praziquantel in serum by high-performance liquid chromatography.

  1983cited by this paper
• A Clinical and Pharmacokinetic Study

  1983influential reference
• Effect of praziquantel on clinical-chemical parameters in healthy and schistosome-infected mice.

  1980cited by this paper
• Drug-polyvinylpyrrolidone (PVP) dispersions. A differential scanning calorimetric study

  1980cited by this paper
• Altered drug metabolism in hepatosplenic schistosomiasis.

  1979cited by this paper
• Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes

  1978influential reference
• Praziquantel, a new broad-spectrum antischistosomal agent

  1977cited by this paper
• Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies.

  1976cited by this paper
• The influence of polyvinylpyrrolidone on the dissolution properties of hydroflumethiazide

  1975cited by this paper
• Pharmaceutical applications of solid dispersion systems.

  1971cited by this paper
• Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin.

  1969influential reference
• Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates.

  1969influential reference
• Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues.

  1968cited by this paper
• An improved perfusion technique for recovering adult schistosomes from laboratory animals.

  1967cited by this paper
• New approach to the screening of drugs in experimental schistosomiasis mansoni in mice.

  1962cited by this paper

• Amorphous Solid Dispersion Formation for Enhanced Release Performance of Racemic and Enantiopure Praziquantel

  2024cites this paper
• Anti-Schistosomal activity and ADMET properties of 1,2,5-oxadiazinane-containing compound synthesized by visible-light photoredox catalysis

  2024cites this paper
• Praziquantel Fifty Years on: A Comprehensive Overview of Its Solid State

  2023cites this paper
• Praziquantel-encapsulated niosomes against Schistosoma mansoni with reduced sensitivity to praziquantel

  2022cites this paper
• Revisiting the Dissolution of Praziquantel in Biorelevant Media and the Impact of Digestion of Milk on Drug Dissolution

  2022cites this paper
• Tunable Polymeric Mixed Micellar Nanoassemblies of Lutrol F127/Gelucire 44/14 for Oral Delivery of Praziquantel: A Promising Nanovector against Hymenolepis nana in Experimentally-Infected Rats

  2022cites this paper
• Itraconazole, a cytochrome P450 inhibitor, enhanced the efficacy of praziquantel against Schistosoma mansoni infection and alleviated liver injury in mice.

  2022cites this paper
• Niosomal versus nano-crystalline ivermectin against different stages of Trichinella spiralis infection in mice

  2021cites this paper
• AbstractActivity and pharmacokinetics of a praziquantel crystalline polymorph in the Schistosoma mansoni mouse model.

  2019cites this paper
• A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection

  2019cites this paper
• Disodium salt of glycyrrhizic acid – A novel supramolecular delivery system for anthelmintic drug praziquantel

  2019cites this paper
• Praziquantel systems with improved dissolution rate obtained by high pressure homogenization.

  2018cites this paper
• Interacción de prazicuantel con excipientes inorgánicos micro- y nanoestructurados

  2018cites this paper
• Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation

  2018cites this paper
• The first comprehensive study of praziquantel effects in vivo and in vitro on European liver fluke Opisthorchis felineus (Trematoda).

  2015cites this paper
• Praziquantel in a Clay Nanoformulation Shows More Bioavailability and Higher Efficacy against Murine Schistosoma mansoni Infection

  2015cites this paper